These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 27872236)

  • 1. Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2).
    Bogman K; Schwab D; Delporte ML; Palermo G; Amrein K; Mohr S; De Vera Mudry MC; Brown MJ; Ferber P
    Hypertension; 2017 Jan; 69(1):189-196. PubMed ID: 27872236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: Utility of monkey as a surrogate for human.
    Cerny MA; Csengery A; Schmenk J; Frederick K
    J Steroid Biochem Mol Biol; 2015 Nov; 154():197-205. PubMed ID: 26303746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rhesus monkey model for concurrent analyses of in vivo selectivity, pharmacokinetics and pharmacodynamics of aldosterone synthase inhibitors.
    Cai TQ; Stribling S; Tong X; Xu L; Wisniewski T; Fontenot JA; Struthers M; Akinsanya KO
    J Pharmacol Toxicol Methods; 2015; 71():137-46. PubMed ID: 25304940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disorders of the aldosterone synthase and steroid 11beta-hydroxylase deficiencies.
    Peter M; Dubuis JM; Sippell WG
    Horm Res; 1999; 51(5):211-22. PubMed ID: 10559665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of polymorphisms in the gene encoding aldosterone synthase (CYP11B2) on steroid synthesis and blood pressure regulation.
    Connell JM; Fraser R; MacKenzie SM; Friel EC; Ingram MC; Holloway CD; Davies E
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):243-7. PubMed ID: 15134824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone synthase inhibition in humans.
    Azizi M; Amar L; Menard J
    Nephrol Dial Transplant; 2013 Jan; 28(1):36-43. PubMed ID: 23045428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor.
    Shimizu H; Tortorici MA; Ohta Y; Ogawa K; Rahman SMA; Fujii A; Hiraga Y; Kawai M; Sugimoto-Kawabata K; van Iersel MT; van Lier JJ; Djedjos S; Slingsby BT; Rodman DM
    Clin Transl Sci; 2024 Aug; 17(8):e70000. PubMed ID: 39152532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase.
    Sloan-Lancaster J; Raddad E; Flynt A; Jin Y; Voelker J; Miller JW
    J Renin Angiotensin Aldosterone Syst; 2017; 18(3):1470320317717883. PubMed ID: 28814143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adrenal cortex remodeling and functional zona glomerulosa hyperplasia in primary aldosteronism.
    Boulkroun S; Samson-Couterie B; Dzib JF; Lefebvre H; Louiset E; Amar L; Plouin PF; Lalli E; Jeunemaitre X; Benecke A; Meatchi T; Zennaro MC
    Hypertension; 2010 Nov; 56(5):885-92. PubMed ID: 20937967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells.
    Ehmer PB; Bureik M; Bernhardt R; Müller U; Hartmann RW
    J Steroid Biochem Mol Biol; 2002 Jun; 81(2):173-9. PubMed ID: 12137808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 18-hydroxylated steroids on corticosteroid production by human aldosterone synthase and 11beta-hydroxylase.
    Fisher A; Friel EC; Bernhardt R; Gomez-Sanchez C; Connell JM; Fraser R; Davies E
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4326-9. PubMed ID: 11549669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary potassium supplementation and sodium restriction stimulate aldosterone synthase but not 11 beta-hydroxylase P-450 messenger ribonucleic acid accumulation in rat adrenals and require angiotensin II production.
    Tremblay A; Parker KL; Lehoux JG
    Endocrinology; 1992 Jun; 130(6):3152-8. PubMed ID: 1597135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: comparison with the 11beta-hydroxylase inhibitor metyrapone.
    Rigel DF; Fu F; Beil M; Hu CW; Liang G; Jeng AY
    J Pharmacol Exp Ther; 2010 Jul; 334(1):232-43. PubMed ID: 20354176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydrobenzisoxazole-4-one compounds are novel selective inhibitors of aldosterone synthase (CYP11B2) with in vivo activity.
    Meyers K; Cogan DA; Burke J; Arenas R; Balestra M; Brown NF; Chen Z; Cerny MA; Clifford HE; Colombo F; Fader L; Frederick KS; Guo X; Goldberg D; Hornberger KR; Kugler S; Lord J; Marshall DR; Moss N; Parmentier JH; Richman JR; Schmenk J; Weldon SM; Yu M; Zhang M
    Bioorg Med Chem Lett; 2018 Mar; 28(5):979-984. PubMed ID: 29254646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemistry of aldosterone synthase leads the way to the pathogenesis of primary aldosteronism.
    Nishimoto K; Koga M; Seki T; Oki K; Gomez-Sanchez EP; Gomez-Sanchez CE; Naruse M; Sakaguchi T; Morita S; Kosaka T; Oya M; Ogishima T; Yasuda M; Suematsu M; Kabe Y; Omura M; Nishikawa T; Mukai K
    Mol Cell Endocrinol; 2017 Feb; 441():124-133. PubMed ID: 27751767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism.
    Amar L; Azizi M; Menard J; Peyrard S; Watson C; Plouin PF
    Hypertension; 2010 Nov; 56(5):831-8. PubMed ID: 20837883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of hypertension and hyperaldosteronism in a rodent model of life-long obesity.
    Northcott CA; Fink GD; Garver H; Haywood JR; Laimon-Thomson EL; McClain JL; Pires PW; Rainey WE; Rigsby CS; Dorrance AM
    Endocrinology; 2012 Apr; 153(4):1764-73. PubMed ID: 22355066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic activation of adrenal Gq signaling induces Cyp11b2 expression in the zona fasciculata and hyperaldosteronism.
    van Rooyen D; Lerario AM; Little DW; Ullenbruch MR; Taylor MJ; Gomez-Sanchez CE; Hammer GD; Rainey WE
    Mol Cell Endocrinol; 2024 May; 585():112176. PubMed ID: 38341019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of sulfonylpyrimidines as novel selective aldosterone synthase (CYP11B2) inhibitors.
    Meguro M; Miyauchi S; Kanao-Arisumi Y; Naito S; Suzuki K; Inoue S; Yamada K; Homma T; Chiba K; Nara F; Furuzono S
    Bioorg Med Chem; 2024 Jun; 108():117775. PubMed ID: 38851000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy.
    Schumacher CD; Steele RE; Brunner HR
    J Hypertens; 2013 Oct; 31(10):2085-93. PubMed ID: 24107737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.